Introduction
============

Adequate tissue perfusion is an essential component of oxygenation during high-risk surgery and may improve outcome \[[@B1],[@B2]\]. Careful monitoring of fluid administration by individualized goal-directed therapy (GDT) has been shown to reduce organ failure and hospital stay \[[@B3]-[@B5]\]. As a supplement to routine cardiovascular monitoring, GDT aims to optimize O~2~delivery (DO~2~) through defined goals, based on maximization of flow-related haemodynamic parameters \[[@B6]-[@B10]\], while avoiding hypovolaemia and fluid overload which may alter tissue oxygenation \[[@B11],[@B12]\].

In addition, the use of early warning signals of tissue hypoxia, such as central venous oxygen saturation (ScvO~2~), which reflects important changes in the O~2~delivery/consumption (DO~2~/VO~2~) relationship, has been found to be useful during high-risk surgery \[[@B13]-[@B15]\]. Indeed, previous studies have shown that changes in ScvO~2~closely reflect circulatory disturbances during periods of tissue hypoxia \[[@B16]\], and that low ScvO~2~is associated with increased postoperative complications \[[@B13]-[@B15]\]. Furthermore, by closely monitoring of tissue O~2~extraction, calculated from ScvO~2~, early correction of altered tissue oxygenation with appropriate fluid loading in conjunction with low doses of inotropes was found to reduce postoperative organ failure in patients with poor O~2~utilization \[[@B13]\].

In a recent randomized study of patients treated with an individualized GDT protocol \[[@B17]\], we found that, despite optimization of preload with repeated fluid loading, excessive fluid restriction increased postoperative complications in parallel with reduced ScvO~2~values \[[@B17]\]. The ScvO~2~threshold value for predicting complications (approximately 71%) was similar to those reported previously \[[@B14],[@B15]\]. Significant ScvO~2~fluctuations may occur during both surgery and sepsis, and high ScvO~2~values do not necessarily reflect changes in DO~2~and macrocirculatory adequacy \[[@B18],[@B19]\], which may therefore limit the clinical relevance of ScvO~2~in routine practice. Persistent tissue hypoperfusion with increased ScvO~2~and O~2~extraction defects might be related to microcirculatory and/or mitochondrial failure \[[@B19],[@B20]\].

Interestingly, central venous-to-arterial PCO~2~(Pcv-aCO~2~), with central venous PCO~2~as a surrogate for mixed venous PCO~2~\[[@B21]\], has recently been proposed as a useful tool for GDT in ICU-septic patients to identify persistent hypoperfusion when a ScvO~2~\> 70% has been reached \[[@B20]\]. Decreased tissue blood flow (ischemic hypoxia) represents the major determinant in increased P(v-a)CO~2~\[[@B22]\], and P(v-a)CO~2~could therefore be considered as an indicator of adequate venous blood flow to remove CO~2~produced by peripheral tissues \[[@B23],[@B24]\].

The results of a previous study, which included patients treated with intraoperative GDT \[[@B17]\], were used to investigate whether P(cv-a)CO~2~is useful for discriminating patients at risk of developing postoperative complications. It was hypothesized that P(cv-a)CO~2~may be a useful complementary tool when a threshold ScvO~2~value has been reached by individualized GDT during major abdominal surgery.

Materials and methods
=====================

Patients
--------

The study that provided data \[[@B17]\] used here was approved by our Institutional Review Board, and all patients provided written informed consent. Data were collected from eligible patients with an ASA score of I to III scheduled for surgery with an expected duration of \> 60 minutes. Surgical procedures included colon/rectum resections, gastric resections, duodenopancreatectomy and hepatectomy. Exclusion criteria included: age \< 18 years, body mass index \> 35 kg m^-2^, pregnancy, chronic obstructive pulmonary disease with forced expiratory volume in 1 sec \< 50%, emergency surgery, coagulopathy, sepsis or systemic inflammatory response syndrome \[[@B25]\], significant hepatic (prothrombin ratio \< 50%, factor V \< 50%) or renal failure (creatinine \> 50% upper limit of normal value), and those in whom epidural analgesia was contraindicated.

Study protocol
--------------

The protocol and design of the original study have been described in detail elsewhere \[[@B17]\]. Briefly, patients were randomly assigned by a concealed allocation approach (computer-generated codes), using opaque sealed envelopes containing the randomization schedule, to 6 mL kg^-1^h^-1^(restricted-GDT group) or 12 mL kg^-1^h^-1^(conventional-GDT group) of crystalloids (lactated Ringer\'s solution), reflecting current clinical practice for restricted (R-GDT group) and more conventional (C-GDT group) fluid administration \[[@B26]\]. Study investigators, but not anaesthesiologists, were blinded to treatment assignments. Immediately after induction of anaesthesia, an oesophageal Doppler probe (HemoSonic 100, Arrow International, Everett, MA, USA) was inserted and adjusted to obtain the highest velocity signal from the descending aorta. Respiratory variations in peak aortic flow velocity (deltaPV) were monitored as described previously \[[@B27],[@B28]\], and stroke volume and cardiac output were recorded continuously. Additional fluid boluses of 250 mL hydroxethylstarch (HES 130/0.4, Voluven^®^; Fresenius-Kabi, Bad Hamburg, Germany) were given in order to maintain deltaPV below 13% \[[@B28]\]. The fluid challenge was repeated (up to 50 mL kg^-1^), if necessary, until deltaPV was corrected. In other cases (deltaPV \< 13% and evidence of haemodynamic instability), a vasoactive/inotropic support (ephedrine chlorhydrate or dobutamine) could be added. Blood was transfused in order to maintain haemoglobin \> 8 g dL^-1^in all patients, or \> 10 g dL^-1^in patients with a history of coronary artery disease. Perioperative management was similar in all patients except for the basal rate of intraoperative crystalloids.

Data collection and outcome measures
------------------------------------

Preoperatively, patients were equipped with central venous (positioned with the tip within the superior vena cava) and arterial catheters. Arterial and central venous blood gas analyses were performed by intermittent blood sampling and co-oximetry (IL Synthesis, Instrumentation Laboratory^®^, Lexington, MA, USA) 10 minutes before surgery (baseline), hourly throughout surgery and until discharge from the post-acute care unit (PACU). This equipment was calibrated each hour, and routine quality control checks were performed. Anaesthesiologists were blinded to ScvO~2~and Pcv-aCO~2~measurements during the course of surgery, which were, therefore, not used to guide clinical management at any stage of the study.

During surgery, the following parameters were recorded: electrocardiogram, pulse oximetry, invasive arterial pressure, cardiac output, oxygen delivery index (DO~2~i), the infused volume of crystalloids, HES, the need for packed red blood cells (PRBCs) and vasoactive/inotrope support, and urine output. Serum lactate, haemoglobin, creatinine, C-reactive protein (CRP), procalcitonin (PCT) and albumin levels were measured at PACU admission and during the 48 h following surgery. Minimal ScvO~2~(minScvO~2~) was considered as the lowest value during the course of surgery.

Postoperative complications were recorded systematically and assessed according to previously defined criteria \[[@B6],[@B29],[@B30]\]. For the purpose of this study, and to assess the effect of abnormal perfusion on tissue oxygenation, we focused specifically on postoperative septic complications, which seem the most relevant clinically in the context of digestive surgery. Diagnosis of postoperative sepsis was based on international consensus guidelines \[[@B25]\]. Infection consisted of postoperative intraabdominal abscesses, wound infections, pneumonia and urinary tract infections. Cardiovascular (congestive heart failure, pulmonary embolism), postoperative haemorrhage and reintervention, neurological (confusion), renal failure and respiratory complications (pneumothorax and pulmonary embolism) complications were not included in the data analysis, except if associated with sepsis. The definition of the complications has been described in detail elsewhere \[[@B17]\]. Pre- and post-operative data, and post-operative complications were recorded by non-research staff blinded to the patient\'s allocation group. These were verified, in accordance with predefined criteria, by a member of the research team unaware of study group allocation. This process involved inspection of radiological investigations, laboratory data and clinical assessment.

Statistical analysis
--------------------

Data in tables are presented as means ± standard deviation (SD) when normally distributed, as medians (interquartile range) when not normally distributed, or as a percentage of the group from which they were derived for categorical data. The chi^2^test was used to compare qualitative data. Qualitative and quantitative data were compared using the Student\'s *t*-test or analysis of variance (ANOVA) when normally distributed (and variance were equivalent), or the Mann-Whitney U-test or Kruskal-Wallis H test in other circumstances. A multivariate analysis of variance (MANOVA) was used to explore longitudinal data. Multiple logistic regression was employed to identify independent risk factors for postoperative complications. The results of logistic regression are reported as adjusted odds ratios with 95% confidence intervals (CI). The robustness of the model was assessed using a Hosmer-Lemeshow Goodness-of-Fit-Test \[[@B31]\]. Receiver operator characteristic (ROC) curves were constructed to identify optimal cut-off values for outcome associations. The optimal cut-off was defined as the value associated with the highest sum of sensitivity and specificity (Youden\'s index). Analysis was performed using SEM software \[[@B32]\] and significance was set at *P*\< 0.05.

Results
=======

Complete follow-up data were collected from 70 patients included in the original study between May and December 2008 (Figure [1](#F1){ref-type="fig"}). Thirty patients developed postoperative complications (58% of the R-GDT group and 26% of the C-GDT group, *P*\< 0.01), including 24 who developed at least one of the following: postoperative sepsis (*n*= 21), intra-abdominal abscess (*n*= 16), pneumonia (*n*= 7) and urinary tract infection (*n*= 4). There were six (8%) who had postoperative acute lung injuries or acute respiratory distress syndrome but none of them was associated with sepsis, and was, therefore, not included in the data analysis. There was no abdominal syndrome. There were two deaths (one in each group, *P*= 0.50). ScvO~2~and P(cv-a)CO~2~data were available for all patients. The demographics and commonly measured biological variables for the study participants are shown in Table [1](#T1){ref-type="table"}. Surgical procedures consisted of colon/rectum resections (43%), duodenopancreatectomy (20%), gastrectomy (21%) and hepatectomy (16%), and were equally distributed (*P*= 0.87). There were no differences in operative time and blood loss between the two groups: 248 ± 42 *vs*. 233 ± 62 min (*P*= 0.21) and 326 ± 215 *vs*. 357 ± 373 ml (*P*= 0.68), respectively, in patients with and without complications. All patients were extubated within two hours after surgery.

![**Flow diagram of the original study**.](cc9310-1){#F1}

###### 

Demographic and biological data at inclusion for patients with and without postoperative complications

                                Patients with complications (*n*= 24)   Patients without complications (*n*= 46)   *P*
  ----------------------------- --------------------------------------- ------------------------------------------ ------
  **Demographic**                                                                                                  
   Age (years)                  60 ± 13                                 62 ± 13                                    0.61
   Sex M/F (%)                  62/38                                   52/48                                      0.41
   BMI (kg m^-2^)               28 ± 7                                  25 ± 3                                     0.06
   P-POSSUM score               35 ± 6.6                                33 ± 5.6                                   0.21
   ASA score I/II/III           12/63/25                                11/72/17                                   0.71
   Hypertension (%)             54                                      50                                         0.74
   Cardiac failure (%)          8                                       9                                          0.95
   Ischemic heart disease (%)   8                                       13                                         0.55
   Diabetes mellitus (%)        17                                      15                                         0.87
   COPD (%)                     17                                      13                                         0.68
   Neoplasia (%)                91                                      85                                         0.41
  **Biological data**                                                                                              
   Haemoglobin (g L^-1^)        12 ± 2                                  13 ± 2                                     0.12
   Haematocrit (%)              37 ± 5                                  39 ± 4                                     0.14
   Albumin (g L^-1^)            36 ± 4                                  35 ± 4                                     0.76
   Prealbumin (g L^-1^)         0.25 ± 0.07                             0.24 ± 0.06                                0.48
   Creatinine (μmol L^-1^)      82 ± 31                                 78 ± 23                                    0.52
   Procalcitonin (mg L^-1^)     0.07 ± 0.04                             0.08 ± 0.11                                0.76
   CRP (mg L^-1^)               6 ± 7                                   7 ± 16                                     0.74
   Lactate (mmol L^-1^)         1.4 ± 0.6                               1.3 ± 0.5                                  0.48

Data are presented as means ± SD, or absolute values (%).

Abbreviations: ASA, American Society of Anaesthesiology physical status; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; P-POSSUM, Portsmouth Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity.

The amounts and types of fluid infused intraoperatively are listed in Table [2](#T2){ref-type="table"}. There was no difference in the total volume of fluid infused between groups (*P*= 0.44), although less crystalloids were administered in patients with complications (*P*\< 0.01). Additional fluid boluses were also significantly higher in these patients (*P*\< 0.01). There was no difference in blood transfusion and in the number of patients who required ephedrine chlorhydrate and dobutamine (Table [2](#T2){ref-type="table"}). There were no relevant differences in the principal haemodynamic (Figure [2](#F2){ref-type="fig"}) and biological variables in patients with and without complications, except for haemoglobin concentration (11.5 ± 1.3 vs. 12.2 ± 1.1 g dL^-1^, *P*= 0.04 at the end of surgery) and excess bases (Table [3](#T3){ref-type="table"}). There was also no relevant difference regarding serum lactate concentration: (3.1 ± 2.5 *vs*. 2.3 ± 1.4 mmol L^-1^, *P*= 0.16 and 1.7 ± 0.8 vs. 1.6 ± 0.6 mmol L^-1^, *P*= 0.59 at PACU admission and at postoperative Day 1, respectively) nor in serum creatinine between patients who did and did not develop postoperative complications.

###### 

Intraoperative fluid management in patients with and without postoperative complications

                                               Patients with complications (*n*= 24)   Patients without complications (*n*= 46)   *P*
  -------------------------------------------- --------------------------------------- ------------------------------------------ ---------
  Total volume of fluid infused (mL)           4,725 (3,600 to 5,300)                  4,525 (3,850 to 6,000)                     0.44
  Total volume of crystalloids infused (mL)    3,255 (2,760 to 4,300)                  4,100 (2,760 to 5,660)                     0.04
  Total volume of colloids infused (mL)        750 (680 to 1,250)                      250 (60 to 500)                            \< 0.01
  Fluid challenge                                                                                                                 
   No. of challenge per patient                4 ± 2                                   2 ± 2                                      \< 0.01
   No. (%) of patients who needed              21 (87)                                 34 (74)                                    0.19
  Blood transfusion, N (%) of patients         6 (25%)                                 7 (15%)                                    0.31
  Urine output (mL)                                                                                                               
   Intraoperative                              600 (390 to 800)                        500 (300 to 975)                           0.46
   Day 1                                       1,350 (800 to 1,950)                    2,000 (1,350 to 3,100)                     0.001
   Day 2                                       2,000 (1,150 to 2,500)                  2,450 (1,525 to 3,000)                     0.45
  Vasoactive support                                                                                                              
   Ephedrine chlorhydrate, N (%) of patients   20 (83%)                                43 (93%)                                   0.18
   Dobutamine, N (%) of patients               0                                       1                                          NR

Data are presented as means ± SD, medians (interquartile range) or absolute values (%). NR, not related.

![**Cardiac index, oxygen delivery index (DO~2~i), stroke volume and mean arterial pressure (MAP) in patients who did (*n*= 24) and did not (*n*= 46) develop postoperative complications**. There was no difference in any variable between groups at any time point. Data are expressed as means ± 95% CI.](cc9310-2){#F2}

###### 

Intraoperative biological data

                              Patients with complications (*n*= 24)   Patients without complications (*n*= 46)   *P*
  --------------------------- --------------------------------------- ------------------------------------------ -------
  **Arterial pH**                                                                                                
   Baseline                   7.42 ± 0.03                             7.43 ± 0.04                                0.27
   T 1H                       7.39 ± 0.04                             7.41 ± 0.04                                0.11
   T 2H                       7.39 ± 0.04                             7.40 ± 0.02                                0.17
   T 3H                       7.38 ± 0.05                             7.39 ± 0.03                                0.78
   End of surgery             7.37 ± 0.05                             7.38 ± 0.05                                0.26
  **Arterial PO~2~, mmHg**                                                                                       
   Baseline                   186 ± 39                                195 ± 52                                   0.59
   T 1H                       185 ± 43                                180 ± 41                                   0.56
   T 2H                       173 ± 44                                179 ± 37                                   0.61
   T 3H                       172 ± 43                                178 ± 35                                   0.46
   End of surgery             178 ± 44                                181 ± 37                                   0.59
  **Arterial PCO~2~, mmHg**                                                                                      
   Baseline                   36 ± 5                                  36 ± 4                                     0.90
   T 1H                       37 ± 4                                  36 ± 3                                     0.41
   T 2H                       37 ± 4                                  36 ± 3                                     0.53
   T 3H                       36 ± 5                                  36 ± 3                                     0.62
   End of surgery             36 ± 5                                  37 ± 3                                     0.36
  **BE, mmol L^-1^**                                                                                             
   Baseline                   -1.7 ± 4.3                              -0.5 ± 2.6                                 0.71
   T 1H                       -3.2 ± 2.7                              -1.1 ± 2.2                                 0.02
   T 2H                       -2.6 ± 2.9                              -1.5 ± 2.1                                 0.31
   T 3H                       -2.4 ± 2.8                              -2.4 ± 2.2                                 0.65
   End of surgery             -4.0 ± 2.6                              -2.8 ± 2.7                                 0.11
  **SaO~2~, %**                                                                                                  
   Baseline                   98 ± 1.1                                99 ± 0.8                                   0.03
   T 1H                       98 ± 1.0                                99 ± 0.6                                   0.001
   T 2H                       98 ± 1.4                                98 ± 0.8                                   0.025
   T 3H                       98 ± 1.2                                98 ± 1.0                                   0.16
   End of surgery             98 ± 0.8                                98 ± 0.7                                   0.21

Data are presented as means ± SD.

BE, base excess; SaO~2~, arterial saturation of oxygen; T, time.

Association with outcome
------------------------

At baseline there was no difference in ScvO~2~values between patients who did and did not develop postoperative complications (82 ± 10 vs. 81 ± 9%, respectively, *P*= 0.75) (Figure [3a](#F3){ref-type="fig"}). Compared with uncomplicated patients, mean ScvO~2~(78 ± 4 vs. 81 ± 4%, *P*= 0.017) and minScvO~2~(67 ± 6 vs. 72 ± 6%, *P*= 0.0017) were both lower in patients with complications. Univariate analysis identified four variables associated with postoperative complications: minScvO~2~(*P*= 0.0028), treatment group (C-GDT and R-GDT, *P*= 0.0067), BMI (*P*= 0.017) and the need for additional fluid bolus (*P*= 0.035). Multivariate analysis showed that the need for additional fluid bolus (OR = 1.46 (95% CI: 1.12 to 2), *P*= 0.005) and minScvO~2~\< 70% (OR = 4.0 (95% CI: 1.23 to 12.5}, *P*= 0.019) were independently associated with postoperative complications. The area under the ROC curve for ScvO~2~was 0.736 (95 CI%: 0.61 to 0.86) according to the occurrence of postoperative complications. The optimal ScvO~2~value was 70.6% (sensitivity 72.9%, specificity 71.4%) for discrimination of patients who did and did not develop complications. Intraoperative characteristics of patients with mean ScvO~2~\> 71% who did and did not develop postoperative complications are listed in Table [4](#T4){ref-type="table"}.

![**Trends in ScvO~2~(a) and P(cv-a)CO~2~(b) in patients who did (*n*= 24) and did not (*n*= 46) develop postoperative complications**. Data are expressed as means ± 95% CI. \* *P*\< 0.05.](cc9310-3){#F3}

###### 

Intraoperative haemodynamic data and fluid management in patients with mean ScvO~2~\> 71%

                                               Patients with complications (*n*= 10)   Patients without complications (*n*= 36)   *P*
  -------------------------------------------- --------------------------------------- ------------------------------------------ ------
  CI, L min^-1^m^-2^                                                                                                              
   Baseline                                    2.9 ± 0.8                               2.7 ± 0.5                                  0.33
   Mean                                        3.0 ± 0.7                               2.9 ± 0.5                                  0.94
   End of surgery                              3.2 ± 0.7                               3.1 ± 0.6                                  0.79
  DO~2~i, mL min^-1^m^-2^                                                                                                         
   Baseline                                    497 ± 94                                510 ± 126                                  0.73
   Mean                                        500 ± 73                                518 ± 108                                  0.74
   End of surgery                              502 ± 74                                527 ± 113                                  0.65
  SV, mL                                                                                                                          
   Baseline                                    75 ± 13                                 74 ± 19                                    0.52
   Mean                                        79 ± 10                                 78 ± 17                                    0.47
   End of surgery                              82 ± 14                                 82 ± 20                                    0.84
  MAP, mmHg                                                                                                                       
   Baseline                                    76 ± 14                                 78 ± 17                                    0.93
   Mean                                        76 ± 8                                  79 ± 11                                    0.81
   End of surgery                              75 ± 7                                  79 ± 10                                    0.37
  Total volume of fluid Infused                                                                                                   
   Crystalloids, mL                            3,375 (2,712 to 4,455)                  4,250 (2,700 to 6,000)                     0.18
   Colloids, mL                                5 (500 to 1,188)                        250 (0 to 500)                             0.11
  Blood transfusion, N (%) of patients         2 (20%)                                 8 (22%)                                    0.63
  Vasoactive support                                                                                                              
   Ephedrine chlorhydrate, N (%) of patients   8 (80%)                                 34 (94%)                                   0.15
   Dobutamine, N (%) of patients               0                                       1                                          NR

Data are presented as means ± SD, median (interquartile range) or absolute values (%).

Abbreviations: CI, cardiac index; DO~2~i, oxygen delivery index; MAP, mean arterial pressure; NR, not related; ScvO~2,~central venous oxygen saturation; SV, stroke volume.

Trends in P(cv-a)CO~2~
----------------------

At baseline there was no difference in P(cv-a)CO~2~values between patients with and without complications (*P*= 0.22) (Figure [3b](#F3){ref-type="fig"}). Mean P(cv-a)CO~2~was larger in patients who developed complications than in those who did not (7.8 ± 2 vs. 5.6 ± 2 mmHg, *P*\< 10^-6^). The area under the ROC curve for P(cv-a)CO~2~was 0.751 (95% CI: 0.71 to 0.79). The best cut-off P(cv-a)CO~2~value was 6 mmHg (sensitivity 79%, specificity 66%, positive predictive value 56%, negative predictive value 85%) for discrimination of patients who did and did not develop complications. When we considered P(cv-a)CO~2~with overall complications (not only those associated with sepsis) in all of the 30 patients, the difference between patients who did and did not develop complications still remained significant. We constructed the ROC curve and found that a P(cv-a)CO~2~of 6 mmHg predicted the occurrence of complications with 75% sensitivity, 50% specificity, predictive positive value of 0.13 and predictive negative value of 0.95 (AUC 0.648, 95% CI 0.58 to 0.72).

In patients with ScvO~2~≥71%, mean P(cv-a)CO~2~was larger in patients who developed postoperative complications than in patients with ScvO~2~≥71% who did not (7.7 ± 2 *vs*. 5 ± 2 mmHg, respectively, *P*\< 10^-6^). The area under the ROC curve for P(cv-a)CO~2~was 0.785 (95% CI: 0.74 to 0.83) with 5 mmHg as the best threshold value (sensitivity 96%, specificity 54%, positive predictive value 41%, negative predictive value 98%) for discrimination of patients with ScvO~2~≥71% who did and did not develop postoperative complications (Figure [4](#F4){ref-type="fig"}).

![**Individual values of P(cv-a)CO~2~according to the occurrence of postoperative complications in patients with ScvO~2~≥71%**. Abbreviations: C, patients with complications; UC, patients without complications.](cc9310-4){#F4}

Discussion
==========

Recently published data clearly demonstrate that low ScvO~2~during major abdominal surgery is associated with an increased risk of postoperative complications \[[@B13]-[@B15]\]. In this study, using Doppler-derived deltaPV as a goal-directed approach, it was observed that high ScvO~2~(≥71%) did not necessarily preclude postoperative complications. In this context, the presence of a P(cv-a)CO~2~value \> 5 mmHg may be a useful complementary tool to identify patients with ScvO~2~≥71% who might remain insufficiently optimized haemodynamically.

There is growing evidence that individualized fluid loading through goal-directed protocols, titrated by dynamic indices of either flow or preload, improves patient outcome, and is superior to the assessment of standard haemodynamic parameters such as mean arterial pressure (MAP), heart rate or central venous pressure, to prevent inadequate or excessive fluid administration \[[@B4],[@B9],[@B33],[@B34]\]. Although the underlying mechanisms remain controversial, most goal-directed therapy (GDT) protocols include fluid loading, alone or combined with inotropes, to prevent O~2~debt by maintaining tissue perfusion \[[@B3]\]. In our recently published randomized study of patients treated with an individualized oesophageal Doppler-guided fluid substitution protocol, we found that crystalloid restriction (6 *vs*. 12 mL kg^-1^h^-1^) was associated with increased postoperative complications \[[@B17]\]. Interestingly, the results also indicated that individualized optimization of preload by colloid loading might not have been sufficient to promote optimal tissue perfusion and oxygenation, as indicated by reduced ScvO~2~values (69 ± 6 vs. 72 ± 6 mmHg, *P*= 0.04) in the restricted-GDT group of patients \[[@B17]\].

Although the prognostic significance of reduced ScvO~2~and the benefit of its normalization in early goal-directed protocols have been proposed \[[@B13],[@B19],[@B35]\], both normal and high ScvO~2~values do not preclude microcirculatory failure \[[@B19]\]. In this context, in patients treated with an early GDT-based sepsis resuscitation protocol, Jones and colleagues \[[@B36]\] and Vallee and colleagues \[[@B20]\] showed that either lactate clearance or P(cv-a)CO~2~might be useful to identify persistent tissue hypoperfusion when the ScvO~2~goal has been reached with apparent normal DO~2~/VO~2~ratio. It was also observed that, in surgical patients, an individualized preload-targeted fluid loading to maintain tissue perfusion was not sufficient to prevent significant differences in outcome \[[@B17]\]. Interestingly, mean P(cv-a)CO~2~was larger in patients with complications with a \"normalized\" DO~2~/VO~2~ratio (ScvO~2~≥71%), than in patients without complications, with 5 mmHg as the best threshold value. According to ScvO~2~, CI and DO~2~i values, enlarged P(cv-a)CO~2~could be explained by a certainly small but persistent tissue hypoperfusion degree in patients who go on to develop postoperative complications. The increase in venous PCO~2~would reflect a state of insufficient flow relative to CO~2~production \[[@B37]\]. This condition has been demonstrated previously \[[@B22],[@B38]\]. Indeed, Vallet and colleagues \[[@B22]\] evidenced that the venous-to-arterial CO~2~gap (PCO~2~gap) increased during low blood flow-induced tissue hypoxia (ischemic hypoxia) while it remained unchanged during hypoxemia-induced hypoxia (hypoxic hypoxia).

These results are in agreement with those of Bakker and colleagues \[[@B24]\] who showed that, in patients with septic shock, the PCO~2~gap was smaller in survivors than in non-survivors, despite quite similar CI, DO~2~and VO~2~values. In septic shock patients, characterized by an increased PCO~2~gap and a low flow state, fluid challenge was found to lower the PCO~2~gap while increasing cardiac output \[[@B39]\]. In contrast, no significant changes in cardiac output and PCO~2~gap were found in patients with normal PCO~2~, thus confirming the relationship between an increased PCO~2~gap and insufficient flow \[[@B39]\]. According to our P(cv-a)CO~2~values and the associated trends in both lactate and base excess concentrations (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}), it can be speculated that, despite an optimized preload with fluid challenge, patients with ScvO~2~values ≥71% who developed complications might have had a relatively insufficient flow state and might have benefited from an increased CI as suggested by the study of Donati \[[@B13]\]. Previous reports have shown that, under conditions where O~2~demand exceeds O~2~consumption (VO~2~), ScvO~2~(and O~2~extraction) does not accurately reflect the O~2~demand/DO~2~relationship \[[@B40]\]. According to the modified Fick equation applied to CO~2~, PCO~2~gap is linearly related to CO~2~production (VCO~2~) and inversely related to CI \[[@B23]\]. Considering the respiratory quotient (VCO~2~/VO~2~ratio), VCO~2~is directly related to O~2~consumption (VO~2~) \[[@B23]\]. Under conditions of adapted cardiac output to VO~2~, even if the CO~2~produced is higher than normal because of an additional anaerobic CO~2~production, in the presence of sufficient flow to wash out the CO~2~produced by the tissues, the PCO~2~gap should not be increased \[[@B22]\]. Conversely, low blood flow can result in a widening of the PCO~2~gap even if no additional CO~2~production occurs because of a CO~2~stagnation phenomenon \[[@B38],[@B41]\]. The association of these situations may explain, in the current study, the combination of \"normal\" ScvO~2~values and increased P(cv-a)CO~2~values. It can be argued that, despite an apparently normal CI during the entire surgical procedure, this condition could relate to a relatively insufficient flow state, and could be associated with an increased O~2~demand and hence increased CO~2~production. Whether increasing in the CI may be beneficial in this situation remains to be evaluated.

These findings may be difficult to generalize because the study has several limitations. First, we are aware that the number of patients included was relatively small which could limit the external validity of the study, and that complementary data are needed to confirm the results. Nevertheless, when we considered that at least one measurement of P(cv-a)CO~2~\> 5 mmHg would represent a risk factor associated with the occurrence of postoperative complications, we found a *post-hoc*power of 52%. Furthermore, when we considered the number of episodes of P(cv-a)CO~2~, we found that more than or equal to three episodes of P(cv-a)CO~2~\> 5 mmHg was associated with a 20% risk of postoperative complications (with a post-hoc power calculation \> 90%). Second, while the threshold ScvO~2~value is very similar to that described previously in a comparable surgical population, the optimal threshold P(cv-a)CO~2~value of 5 mmHg in line with a 71% ScvO~2~goal might be subject to criticism. It might be considered that a higher ScvO~2~(that is, ≥73%) would represent a more appropriate target value \[[@B40]\]. Third, potential confounders such as hypothermia, which may decrease cellular respiration and, therefore, CO~2~generation \[[@B21]\], might have affected the results. Nevertheless, during the entire surgical procedure, special attention was taken to maintain normothermia. In addition, except for fluid therapy, intraoperative management was similar in the two groups of patients. Although there was a significant difference in the volume of fluids infused, this was not associated with postoperative complications with logistic regression (*P*= 0.16 and *P*= 0.49 for crystalloids and colloids, respectively). Even after adjustment P(cv-a)CO~2~\> 5 mmHg still remains associated with the occurrence of postoperative complications (*P*\< 0.001). Fourth, the use of central venous-to-arterial PCO~2~difference as a surrogate for mixed venous PCO~2~gap might be a further limitation. Nevertheless, it has recently been found that central venous PCO~2~, obtained from a simple central blood sample instead of a pulmonary arterial blood sample, is a valuable alternative to PvCO~2~and that correlation with CI still exists in this context \[[@B21]\]. In addition, measurement of P(cv-a)CO~2~instead of P(v-a)CO~2~may be more convenient in a surgical context.

Conclusions
===========

There is strong support today for the use of individualized goal-directed fluid substitution during high-risk surgery. Although ScvO~2~reflects important changes in the O~2~delivery/consumption relationship, it is speculated that P(cv-a)CO~2~might reinforce the value of ScvO~2~to identify insufficient flow and tissue hypoperfusion during high-risk surgery. In this context, P(cv-a)CO~2~could be a useful complementary tool to ScvO~2~to identify patients who remain inadequately managed when the optimization goal has been reached by volume loading during a GDT protocol. Future research is needed to validate this finding.

Key messages
============

• Early detection and correction of tissue hypoperfusion were shown to improve outcome during high-risk surgery.

• Central venous-to-arterial CO~2~difference might serve as a complementary tool to ScvO~2~to identify insufficient flow when individualized optimization of intravascular status has been reached with fluid loading.

• Larger randomized trials are now required to confirm the benefit of this approach.
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